dr. koprivnikar discusses flt3 inhibitors in hematologic malignancies
Published 6 years ago • 222 plays • Length 1:44Download video MP4
Download video MP3
Similar videos
-
3:10
three minute thesis final 2018 — silvia pregnolato
-
2:32
mcrn 003 - the kcd trial
-
12:08
progress report iii - kincső lőrincz
-
1:03
tomosíntesis 3d
-
4:23
francisco pasquel md, mph, ada 2019 – the glargine u300 hospital trial
-
3:06
dilanka fernando 3mt presentation 2018
-
3:08
sf3b1 mutation and atm deletion co-drive leukemogenesis through centromeric r-loop dysregulation
-
22:33
elaine emery
-
8:29
speedband super 7 physician
-
5:09
klonopin/clonazepam recall: what you need to know
-
6:53
results of the phase iii dasision trial and the future of cml treatment
-
2:39
results from the randomized phase iii daunodouble trial
-
1:42
dose escalation of ro7283420, a hla-a2-wt1 cd3 t-cell bispecific antibody, in r/r aml
-
6:35
measuring residual disease in granulocytes to predict relapse after therapy cessation in cml
-
4:18
second-generation flt3 inhibitors in aml: quizartinib
-
1:24
phase i study of cd123 nk cell engager sar443579 in r/r aml, b-all or hr-mds
-
2:44
fran lasowski, 3mt 2013
-
3:25
3min rct: deliver trial
-
14:39
rosa mendez - regulation of cma by pharmacological activators and inhibitors